Purpose: The aim of this article was to develop a protocol for the treatment of oral mucositis induced by chemotherapy and radiotherapy. A pilot trial was conducted with low-intensity laser therapy (GaAlAs/InGaAlP laser) to decrease the lesions’ manifestation time and to promote pain control. Materials and Methods: Fifty patients for whom chemotherapy or chemoradiotherapy was indicated were evaluated in this study. Fifteen patients developed mucositis (30%) and were divided into 3 groups of 5, receiving lowintensitity laser therapy 3 times a week, with a specific dosage in each group. Group A: GaAlAs laser, wavelength 830 nm (infrared), power 70 mW, dose 5 J/cm2; group B: InGaAlP Laser, wavelength 685 nm (red), power 35 mW, dose 5 J/cm2; group C: placebo. The presence and severity of mucositis was clinically evaluated using the WHO scale, and pain was measured by using a visual analogue scale (VAS). The Kruskal-Wallis test was used to test differences among groups. Results were considered statically significant when p < 0.05. Results: The infrared laser 830 nm (Group A) showed therapeutic superiority when compared with the red laser 685 nm (Group B) and the Group C (placebo). Group B showed intermediate results between groups A and C in terms of mucositis duration and the decrease of the lesion grade at 7 and 15 days. However, the pain level after 7 days of the treatment continued to be high compared to Group C (placebo). Conclusions: Low-intensity laser therapy with a 830-nm (infrared) wavelength can be indicated for oral mucositis induced by chemoradiotherapy, due to its better therapy results compared to the red laser (685 nm) and the placebo group in the same application periods.
Keywords: low-intensity laser therapy, oral mucositis, chemotherapy, radiotherapy